Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 7/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 4/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5234117 | 1.00 | PRCP (0.55) | PRCPKDM4EHTR2CTLR2TERT | |
| SCHEMBL29871257 | 0.94 | PRCP (0.50) | PRCPKDM4EHTR2CTLR2TERT | |
| Trifluoroacetic Acid SCHEMBL5231460 | 0.91 | HTR2C (0.48) | PRCPKDM4EHTR2CTLR2TERT | |
| SCHEMBL24158416 | 0.89 | PRCP (0.51) | PRCPKDM4EHTR2CTLR2TERT | |
| SCHEMBL14608315 | 0.86 | PRCP (0.49) | PRCPKDM4EHTR2CTLR2TERT | |
| SCHEMBL14100750 | 0.86 | PRCP (0.55) | PRCPKDM4EHTR2CTLR2TERT | |
| SCHEMBL11796648 | 0.86 | PRCP (0.55) | PRCPKDM4EHTR2CTLR2TERT | |
| SCHEMBL20781317 | 0.84 | PRCP (0.50) | PRCPKDM4EHTR2CTLR2TERT | |
| SCHEMBL11587343 | 0.84 | PRCP (0.60) | PRCPKDM4EHTR2CTLR2EPHX2 | |
| SCHEMBL27953007 | 0.84 | PRCP (0.49) | PRCPKDM4EHTR2CTLR2TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513842-B1 | SUBSTITUTED HEXAHYDROPYRROLO (1,2-A)PYRAZINES, OCTAHYDROPYRIDO(1,2-A)PYRAZINES AND DECAHYDROPYRAZINO(1,2-A)AZEPINES | NOVO NORDISK AS (DK) | 2007-03-07 | — | — | EP | disclosed |
| EP-1513842-B1 | SUBSTITUTED HEXAHYDROPYRROLO (1,2-A)PYRAZINES, OCTAHYDROPYRIDO(1,2-A)PYRAZINES AND DECAHYDROPYRAZINO(1,2-A)AZEPINES | NOVO NORDISK AS (DK) | 2007-03-07 | — | — | EP | disclosed |
| US-7186721-B2 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | NOVO NORDISK A/S (DK) | 2007-03-06 | — | — | US | disclosed |
| US-7186721-B2 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | NOVO NORDISK A/S (DK) | 2007-03-06 | — | — | US | disclosed |
| US-7186721-B2 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | NOVO NORDISK A/S (DK) | 2007-03-06 | — | — | US | disclosed |
| US-20050267116-A1 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | HIGH POINT PHARMACEUTICALS, LLC | 2005-12-01 | — | — | US | disclosed |
| US-6906060-B2 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | NOVO NORDISK A/S (DK) | 2005-06-14 | — | — | US | disclosed |
| EP-1513842-A1 | SUBSTITUTED HEXAHYDROPYRROLO (1,2-A)PYRAZINES, OCTAHYDROPYRIDO(1,2-A)PYRAZINES AND DECAHYDROPYRAZINO(1,2-A)AZEPINES | NOVO NORDISK A/S (DK) | 2005-03-16 | — | — | EP | disclosed |
| US-20040023946-A1 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | VTVX HOLDINGS II LLC | 2004-02-05 | — | — | US | disclosed |
| WO-2003104235-A1 | SUBSTITUTED HEXAHYDROPYRROLO[1,2-A]PYRAZINES, OCTAHYDROPYRIDO[1,2-A]PYRAZINES AND DECAHYDROPYRAZINO[1,2-A]AZEPINES | NOVO NORDISK A/S (DK) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023946-A1 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | HRH2, HRH4, HRH1 | PRCP 2391/4885KDM4E 1409/4885HTR2C 19/4885 |
| US-20050267116-A1 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | HRH2, HRH4, HRH1 | PRCP 1396/4885KDM4E 1365/4885HTR2C 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.